THERAPY DOSSIER · th-91c2131ff668

Dai-Huang-Fu-Zi-Tang (Radix et Rhizoma Rhei, Radix Aconiti Lateralis Praeparata, Radix et Rhizoma Asari, 3:3:1)

Nutraceutical · Multi-herb traditional Chinese decoction; no single ChEMBL entity applicable. ClinicalTrials.gov searched: 0 hits.

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: Multi-herb traditional Chinese decoction; no single ChEMBL entity applicable. ClinicalTrials.gov searched: 0 hits.
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28577538 ↗2017Reported benefit

Dai-Huang-Fu-Zi-Tang alleviates pulmonary and intestinal injury with severe acute pancreatitis via regulating aquaporins in rats.

RatChemical/toxinSprague-DawleyMalen = n = 8 per group in the main experiment (24 rats total); 40…Oral gavage62 mg/kg in the main experiment; 31, 62 and 124 mg/kg teste…First dose at 0 h after induction of severe acute pancreatitis

Model: Severe acute pancreatitis induced by retrograde biliopancreatic duct infusion of 5% sodium taurocholate (0.1 ml/100 g), with secondary lung and intestinal injury

DHFZT reduced lung and intestinal wet/dry ratios and histological injury scores, lowered serum amylase, lipase, endotoxin, TNF-alpha and IL-6 while raising IL-10, and restored AQP1 and AQP5 in lung and AQP1, AQP5 and AQP8 in intestine.

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…